Skip to content
10-Q

Quarterly Report

CNBX PHARMACEUTICALS INC. CNBX

0001683168-23-002379

← back to feed
Filed
Apr 14, 2023 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2023 · Apr 12, 2023 4.97M sh
Cash And Equivalents Q2 2023 · Feb 28, 2023 $47.75K
Cash And Equivalents Q2 2023 · Aug 31, 2022 $117.52K
Current Liabilities Q2 2023 · Feb 28, 2023 $2.47M
Current Liabilities Q2 2023 · Aug 31, 2022 $2.44M
Current Assets Q2 2023 · Feb 28, 2023 $108.84K
Current Assets Q2 2023 · Aug 31, 2022 $198.29K
Total Assets Q2 2023 · Feb 28, 2023 $462.05K
Total Assets Q2 2023 · Aug 31, 2022 $811.17K
Shares Diluted Q2 2023 · Feb 28, 2022 1.23M sh
Shares Diluted Q2 2023 · Feb 28, 2022 1.13M sh
Operating Cash Flow Q2 2023 · Feb 28, 2022 −$1.15M
Stockholders Equity Q2 2023 · Feb 28, 2022 −$648.03K
Stockholders Equity Q2 2023 · Nov 30, 2021 $802.71K
Stockholders Equity Q2 2023 · Aug 31, 2021 $1.81M
Eps Diluted Q2 2023 · Feb 28, 2022 −$1.01
Eps Diluted Q2 2023 · Feb 28, 2022 −$2.27
Eps Basic restated Q2 2023 · Feb 28, 2022 −$1.01
Eps Basic restated Q2 2023 · Feb 28, 2022 −$2.27
Sga Expense Q2 2023 · Feb 28, 2022 $399.69K
Sga Expense Q2 2023 · Feb 28, 2022 $1.07M
Rd Expense Q2 2023 · Feb 28, 2022 $330.58K
Rd Expense Q2 2023 · Feb 28, 2022 $770.62K
Net Income Q2 2023 · Feb 28, 2022 −$1.24M
Net Income Q2 2023 · Feb 28, 2022 −$2.56M
Operating Income Q2 2023 · Feb 28, 2022 −$730.26K
Operating Income Q2 2023 · Feb 28, 2022 −$1.84M